Tongyi Medicine completed the B round of financing, Huimei Capital led the investment

Tongyi Medicine is a pharmaceutical company dedicated to the development of a new generation of targeted tumor drugs. It has a multi-target ligand-drug conjugate (LDC) technology platform with independent intellectual property rights, and has a number of deadly targets for lung cancer, gastric cancer, liver cancer, etc. LDC drugs for the disease enter preclinical studies. Recently, Tongyi Medicine completed the B round of financing, led by Huimei Capital, followed by Yuanfeng Capital, ABC International, Yicun Capital, and old shareholders Tong and Yucheng. A dual-ligand conjugated drug CBP-1008 was successfully launched at an early date, thereby addressing unmet clinical needs and benefiting patients.

This article is reproduced from:
This site is for inclusion only, and the copyright belongs to the original author.

Leave a Comment

Your email address will not be published.